Table 2.
AlloSCT history
| N = 25 | |
|---|---|
| Disease state prior to alloSCT, n (%) | |
| Relapsed/refractory disease | 13 (52) |
| Remission | 7 (28) |
| Unknown | 5 (20) |
| Donor status, n (%) | |
| Matched related donor* | 13 (52) |
| Matched unrelated donor* | 7 (28) |
| Mismatched related donor | 1 (4) |
| Mismatched unrelated donor | 3 (12) |
| Unrelated donor with unknown HLA status | 1 (4) |
| Median interval between alloSCT and next subsequent treatment, mo (range) | 12.5 (2-36) |
| Median interval between alloSCT and first dose of brentuximab vedotin, mo (range) | 42 (6-116) |
*
Considered to be HLA matched at the time of alloSCT.